Last reviewed · How we verify

NCT03233646

Retinal Imaging in Neurodegenerative Disease

Recruiting now Last updated 4 February 2026
What this trial tests

trial testing Retinal and Choroidal Imaging in Alzheimer's Disease in 2,000 participants. Currently enrolling.

Timeline
20 July 2017
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorDuke University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date20 July 2017
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

18 and older, any sex, with Alzheimer's Disease or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Retinal Microvascular and Neurodegenerative Changes in Alzheimer's Disease and Mild Cognitive Impairment Compared with Control Participants.
    Yoon SP, Grewal DS, Thompson AC, Polascik BW, et al · · 2019 · cited 170× · PMID 31174670 · DOI 10.1016/j.oret.2019.02.002
  2. Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease.
    Colligris P, Perez de Lara MJ, Colligris B, Pintor J. · · 2018 · cited 54× · PMID 30151279 · DOI 10.1155/2018/8538573
  3. Longitudinal Analysis of the Retina and Choroid in Cognitively Normal Individuals at Higher Genetic Risk of Alzheimer Disease.
    Ma JP, Robbins CB, Lee JM, Soundararajan S, et al · · 2022 · cited 24× · PMID 35283324 · DOI 10.1016/j.oret.2022.03.001
  4. Longitudinal Analysis of Retinal Microvascular and Choroidal Imaging Parameters in Parkinson's Disease Compared with Controls.
    Kundu A, Ma JP, Robbins CB, Pant P, et al · · 2023 · cited 13× · PMID 38223333 · DOI 10.1016/j.xops.2023.100393
  5. A Convolutional Neural Network Using Multimodal Retinal Imaging for Differentiation of Mild Cognitive Impairment from Normal Cognition.
    Wisely CE, Richardson A, Henao R, Robbins CB, et al · · 2024 · cited 12× · PMID 37877003 · DOI 10.1016/j.xops.2023.100355
  6. Repeatability of Peripapillary OCT Angiography in Neurodegenerative Disease.
    Ma JP, Robbins CB, Stinnett SS, Johnson KG, et al · · 2021 · cited 10× · PMID 36246947 · DOI 10.1016/j.xops.2021.100075
  7. Retinal and Choroidal Changes in Men Compared with Women with Alzheimer's Disease: A Case-Control Study.
    Mirzania D, Thompson AC, Robbins CB, Soundararajan S, et al · · 2022 · cited 10× · PMID 36246183 · DOI 10.1016/j.xops.2021.100098
  8. Multimodal Retinal Imaging Classification for Parkinson's Disease Using a Convolutional Neural Network.
    Richardson A, Kundu A, Henao R, Lee T, et al · · 2024 · cited 7× · PMID 39136960 · DOI 10.1167/tvst.13.8.23

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03233646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing